1. Introduction {#sec1}
===============

A best evidence topic was constructed according to a structured protocol. This is fully described in a previous publication [@bib1].

2. Clinical scenario {#sec2}
====================

You have been referred an 85-year-old man with an asymptomatic thoracoabdominal aortic aneurysm (TAAA) type II (Crawford\'s classification) diagnosed on computed tomography angiogram with a maximum diameter of 68 mm in the descending aorta. Comorbidities include chronic obstructive pulmonary disease (COPD), obesity, diabetes mellitus type II, hypertension, and chronic renal failure. The patient tells you that in view of his age and comorbidities he is keen for a minimally invasive approach and asks you whether endovascular treatment with insertion of multilayer flow modulator stents (MFMS), a new treatment which his family read about on Google, would be a suitable option for him. To confirm the therapeutic option and achieve the best possible outcome in this high-risk patient, you perform a literature review yourself.

3. Three-part question {#sec3}
======================

In \[high-risk patients with thoracoabdominal aortic aneurysm\] are \[multilayer flow modulator stents\] a safe alternative to open surgery for achieving \[better survival and lower morbidity\]?

4. Search strategy {#sec4}
==================

A literature search was performed using PubMed, Ovid, Embase, and Cochrane databases using the terms ("aortic aneurysm, thoracic"\[MeSH Terms\] OR ("aortic"\[All Fields\] AND "aneurysm"\[All Fields\] AND "thoracic"\[All Fields\]) OR "thoracic aortic aneurysm"\[All Fields\] OR ("thoracoabdominal"\[All Fields\] AND "aortic"\[All Fields\] AND "aneurysm"\[All Fields\]) OR "thoracoabdominal aortic aneurysm"\[All Fields\]) AND multilayer\[All Fields\] AND flow\[All Fields\] AND ("stents"\[MeSH Terms\] OR "stents"\[All Fields\] OR "stent"\[All Fields\]).

In addition, the reference lists of the relevant papers were searched. The search was current as of 23rd January 2017.

5. Search outcome {#sec5}
=================

Twenty seven papers were identified using the reported search. Two authors (C.P. and G.G.) independently assessed the titles and abstracts of the identified articles to determine potential relevance. Any disagreement was resolved by discussion or with the opinion of the senior author (T.A.) After reviewing the abstracts, 21 papers were selected to be fully appraised in view of relevance and methods used. From these, 2 were short communications, 2 involved overlap of patient groups (the most recent was included), 6 were irrelevant, one was a narrative review, and one article was in French (all excluded except for the latter). Inclusion criteria included studies of any size, prospective or retrospective in design that assessed outcomes for patients with thoracoabdominal aneurysm. All patients included had to have received appropriate treatment. Exclusion criteria included studies reporting on patients with peripheral or visceral aneurysms. Narrative review articles and studies where the patients had not been sub-grouped according to the anatomical site of the aneurysm to allow distilling of the evidence specifically for thoracoabdominal aneurysms were also excluded. Based on design, number of patients and origin (high volume/specialised centres and national registries) 11 papers were chosen as representative to answer the clinical question.

6. Results {#sec6}
==========

The results of the 11 papers (one meta-analysis, 4 prospective studies, and 6 retrospective studies) are summarised in [Table 1](#tbl1){ref-type="table"}.

7. Discussion {#sec7}
=============

In 2016, Hynes et al. [@bib2] published a meta-analysis of MFMS reviewing data on 171 patients with complex aortic pathology (59.1% had TAAA). They found that the aneurysm-related survival rate was 78.7% at 1 year and 66.6% at 18 months. At 18 months, this rate was 93.3% within the instructions for use (IFU) subgroup in contrast to a rate of 25.6% for patients treated outside the IFU. Technical success was 76.6%, with 95.5% of technical failures occurring in cases performed outside the IFU. All-cause survival rate was 53.7% at 1 year and 37.4% at 18 months. There were no cases of spinal cord ischemia, renal insult or stroke.

Lowe et al. [@bib3] analysed the outcomes of MFMS in 14 patients. Among these, 50% had TAAA. All-cause, aneurysm-related and growth-free survivals were 79%, 86% and 28.5% respectively at 1 year. The 30-day mortality was 7% whilst at a mean follow-up of 22.8 months it reached 50% with one rupture. There were MFMS dislocations in 28.6% of patients with 35% of cases requiring reintervention.

In their prospective study, Bouayed et al. [@bib4] assessed the effects of use of MFMS in 41 aortic lesions. Among these, 20 were TAAA. 30-day mortality was 5.26% due to aneurysmal rupture and myocardial infarction whilst 12-month mortality was 23.68%. The aneurysmal sac was not supplied in 30% of TAAA cases and poorly supplied in 70%. Visceral patency was 100%.

Vaislic et al. [@bib5] evaluated one-year outcomes following the use of MFMS in 23 patients with type II and III TAAA. At 12 months, all-cause mortality was 4%, complete sac thrombosis was achieved in 75% of patients and branch patency rate was 96.5%. Moreover, at 12 months there were reinterventions in 22% of patients and the aneurysm diameter increased in 10% whilst remained stable in 90%.

Sultan et al. [@bib6] presented the results of 103 patients treated with MFMS under IFU. Among the cases, 72.8% had TAAA. At 1 year, aneurysm-related survival was 91.7% (no rupture occurred), all-cause survival was 86.8% and the covered branch patency was 95.3%. The incidence of stroke and paraplegia were 1.9% and 0.99% respectively at 12 months.

In another study, Sultan et al. [@bib7] appraised the consequences of treatment with MFMS outside the IFU in 38 patients, among which 39.5% had TAAA. During the follow up (10.0 ± 6.9 months), all-cause mortality was 89.5%, of which 71.1% were aneurysm-related. At 18 months, overall survival, freedom from aneurysm-related death and rupture-free survival were 17.5%, 25.0% and 31.5% respectively. Visceral branch occlusions were observed in 21% of patients. There were no reported cases of stroke or paraplegia.

Sultan and Hynes [@bib8] retrospectively reviewed 1-year results of 55 patients, of which 56.4% had TAAA, treated with MFMS. At 1 year, aneurysm-related survival was 93.7% (no rupture occurred), all-cause survival was 84.8%, intervention-free survival was 92.4%, and all side branches were patent. Complications included bleeding (7.3%), stroke (3.6%) and reintervention (7.3%).

Henry et al. [@bib9] analysed the use of MFMS in 18 patients (55.5% of which had TAAA). Technical success was 100% and 30-day mortality was 0%. At 8 months, aneurysm-related and all-cause survivals were 100% and 83.3% respectively, with branch patency rate being 100%. In the TAAA group, the mean aneurysm diameter decreased at 6 months.

Pane et al. [@bib10], Debing et al. [@bib11], and Polydorou et al. [@bib12] all reported similar outcomes following treatment of TAAA with MFMS. They concluded that use of the medical device is feasible and seems to be a solution for the management of TAAA. The authors also inferred that MFMS can stabilize aneurysm diameter and ensure the patency of collateral vessels.

When looking collectively at the existing evidence, there are certain important points for consideration. First and foremost, there is a complete absence of randomised controlled trials (RCTs) on the subject. Secondly, there are no long-term follow-up studies. Thirdly, a significant amount of heterogeneity exists in terms of the variety concerning both the anatomy (location) and pathology (type) of aneurysms treated with MFMS. As a result, certain studies contradict others, especially when it comes to reporting mid-term results with some authors concluding that "the treatment of aneurysms with MFMS seems to have encouraging midterm results" [@bib10] whilst others reporting that "the role of MFMS remains unclear" [@bib3]. Despite the many limitations in the literature, there seems to be a consensus that MFMS, when used within their IFU, may represent a valuable option in those patients where open surgery is deemed high-risk. Finally, existing studies also concur that in addition to robust scientific and clinical data, further innovative developments are needed to improve MFMS safety, expand their instructions for use, and enhance their efficacy.

8. Clinical bottom line {#sec8}
=======================

In addition to the mortality associated with open TAAA repair, fundamental risks include compromising the blood flow to the spinal cord and/or viscera. In this context, MFMS appear to represent a safe alternative in the management of complex aneurysms. In this paper, the outcomes in patients with TAAA undergoing endovascular repair with MFMS were evaluated. Several studies showed that the use of MFMS in the treatment of TAAA is associated with a low incidence of complications, including stroke, paraplegia and aneurysm rupture. In addition, these studies demonstrated acceptable rates of aneurysm-related survival and visceral branch patency. On the other hand, undesirable outcomes have been reported when the MFMS is used outside the IFU.

Thus, we conclude that endovascular treatment with MFMS insertion is a safe treatment for TAAA in high-risk patients, associated with maintenance of branch vessel patency, provided they are used in accordance to the IFU. However, a number of limitations must be considered when interpreting this evidence. Firstly, the complete lack of RCTs, secondly, the absence of long-term follow-up studies, and thirdly, the heterogeneity of the pathologies among the different populations studied. Despite these limitations, MFMS appear to offer a suitable and safe alternative to open surgery for TAAA cases where open surgery is deemed high-risk.
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Best evidence papers.

Table 1

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, date and country              Patient Group                                                                                                                                                                                                                                                                                                                                                                                                                                    Study type (level of evidence)                                                      Outcomes                                                  Key results                                                                                                                                                                                            Comments
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hynes et al. [@bib2], Ireland         171 patients (mean age 68.8 years)\                                                                                                                                                                                                                                                                                                                                                                                                              Meta-analysis of observational non-comparative studies and case series (level 2b)   Primary endpoint\                                         Mean follow-up was 9 months\                                                                                                                                                                           Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        TAAA - 59.1% (type I 7.6%; type II 14%; type III 16.4%; type IV 9.9%; unclassified 11.1%)\                                                                                                                                                                                                                                                                                                                                                                                                                                           Aneurysm-related survival\                                Aneurysm-related survival was 78.7% at 1 year and 66.6% at 18 months (mean follow-up 9 months, mean aneurysm diameter 6.7 ± 1.6 cm)\                                                                   MFMS technology is able to treat thoracoabdominal pathology safely\
                                        Descending thoracic aortic aneurysm - 0.6%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \                                                         \                                                                                                                                                                                                      \
                                        AAAs - 22.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Secondary endpoints\                                      Aneurysm-related survival rates at 18 months: 93.3% (MFMS used within the IFU) and 25.6% (MFMS used outside the IFU)\                                                                                  Poor outcomes were explained by a lack of appreciation of the device\'s limitations and its application outside the IFU\
                                        Type B dissections - 11.7%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \                                                         \                                                                                                                                                                                                      \
                                        Saccular aneurysms - 8.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Technical success\                                        Technical success - 76.6% (95% of technical failures occurred in cases that were performed outside of the IFU)\                                                                                        Randomised clinical trials, registries and continued assessment are essential before the MFMS can be widely disseminated\
                                        Arch aneurysms - 4.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                All-cause survival\                                       \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Neurologic complications\                                 All-cause survival were 97.1% at 30 days, 53.7% at 1 year, and 37.4% at 18 months\                                                                                                                     Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Renal impairment\                                         \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Visceral ischemia\                                        No cases of spinal cord ischemia, renal insult, or stroke\                                                                                                                                             The numbers in this review are not enough to enable meaningful subgroup analysis\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Branch vessel patency\                                    \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Aneurysm expansion                                        Branch patency rate of 97.8%                                                                                                                                                                           Poor quality of the data (case reports)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Variety of pathologies

  Lowe et al. [@bib3], United Kingdom   Fourteen patients with mean age of 74.6 years\                                                                                                                                                                                                                                                                                                                                                                                                   Prospective cohort study (level 2a)                                                 Growth-free survival\                                     Mean follow-up of 22.8 months\                                                                                                                                                                         Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA - 50% of the presented pathologies:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Maximal aneurysm diameter\                                At 1 year:\                                                                                                                                                                                            MFMS had little influence on the natural history of complex aortic aneurysms\
                                        Type II - 7.1%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \                                                         All-cause survival - 79%\                                                                                                                                                                              \
                                        Type III - 14.3%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    30 day mortality\                                         Aneurysm - related survival - 86% (one rupture, one perioperative death)\                                                                                                                              The device was unstable and dislocated frequently\
                                        Type IV - 28.6%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \                                                         Growth-free survival - 28.5%\                                                                                                                                                                          \
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Aortic side branch patency\                               Visceral branch patency rate of 98% at 1 year (no embolic episodes or symptoms of ischemia)\                                                                                                           None of the aneurysms treated shrank and the majority of aneurysms in patients who survived over 12 months continued to grow\
                                        Aortic arch aneurysm - 14.3%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \                                                         \                                                                                                                                                                                                      \
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    All complications\                                        Median increase in aneurysm size of 9 mm at 12 months, and of 11 mm at mean follow up\                                                                                                                 The role of MFMS remains unclear\
                                        Perirenal aortic aneurysm - 35.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Reintervention                                            30-day mortality - 7%\                                                                                                                                                                                 Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       At mean follow-up 50% of patients died:\                                                                                                                                                               Small number of patients\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Rupture - 7.1%\                                                                                                                                                                                        \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Myocardial infarction - 14.3% (7.1% procedure-related and 7.1% unrelated at 17 months)\                                                                                                                Variety of pathologies
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       COPD/pneumonia (not device or procedure-related) - 7.1%\                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Multiorgan failure post implantation - 7.1%\                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Unknown - 14.3%\                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       MFMS dislocation in 28.6% of patients\                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Reinterventions in 35% of patients, with 7% of post-re-intervention death                                                                                                                              

  Bouayed et al. [@bib4], Algeria       Thirty eight patients on which 41 procedures were performed on 41 lesion locations\                                                                                                                                                                                                                                                                                                                                                              Prospective cohort study\                                                           Aneurysm location\                                        Mean follow-up was 12 months (1--20 months)\                                                                                                                                                           Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                (level 2a)                                                                          \                                                         \                                                                                                                                                                                                      \
                                        25 male and 13 female\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Aneurysm diameter\                                        "Initial technical success" was 100% with no cases of paraplegia, stroke, or mesenteric ischemia\                                                                                                      Multilayer stents may represent a treatment option for dissection and complex aortic aneurysms in frail patients which would otherwise be at high morbidity and mortality risk (i.e. if they were to undergo open surgery)\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Mean age 63 years (40--84 years)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    30-day and 12-month all-cause mortality\                  Mean length of hospital stay was 7 days (4--14 days)\                                                                                                                                                  The results are of interest with regards to false aneurysms and true aneurysms without significant collateral supply\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         Complications\                                                                                                                                                                                         \
                                        Series divided into 4 groups:-First group: 21 cases (20 thoracoabdominal aneurysms comprising of 2 Crawford type I, 4 type II, 4 type III, 10 type IV, and one aneurysm of the entire thoracic aorta). Average diameter: 71 mm (54--98 mm)-Second group: 7 cases with aneurysms in juxta and infrerenal aorta. Average diameter: 73 mm (62--97 mm)-Third group: 5 cases of false aneurysms-Fourth group: 8 cases of aortic dissection hematoma                                                                                       Complications\                                            \                                                                                                                                                                                                      Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         Three complications relating to the surgical approach occurred, all treated surgically "with success"\                                                                                                 \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Need for open conversion\                                 \                                                                                                                                                                                                      Small number of patients\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         Two patients developed post-operative renal failure, one of them requiring haemodialysis (2.63%)\                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Length of hospital stay                                   \                                                                                                                                                                                                      Heterogeneous groups (in terms of aneurysm type and location)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       There was no need for open conversion\                                                                                                                                                                 \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      No controls\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Mortality\                                                                                                                                                                                             \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      Single centre study
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       30-day mortality was 5.26% One patient died due to aneurysmal rupture in the first postoperative day and one died following a massive myocardial infarction after the procedure\                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       12-month mortality was 23.68% (9 deaths, none related to the aneurysm)                                                                                                                                 

  Vaislic et al. [@bib5], France        Twenty-three high surgical risk patients with mean age of 75.8 years\                                                                                                                                                                                                                                                                                                                                                                            Prospective multicentre non-randomised trial (level 2a)                             Primary endpoints\                                        Follow-up of 12 months\                                                                                                                                                                                Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       All-cause mortality\                                      At 12 months:\                                                                                                                                                                                         Successful endovascular treatment with MFMS\
                                        Type II - 43.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Complete sac thrombosis\                                  All-cause mortality - 4%\                                                                                                                                                                              \
                                        Type III - 56.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Branch vessel patency\                                    Complete sac thrombosis in 75% of patients\                                                                                                                                                            Radiographic evidence of progressive sac thrombus formation\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         Covered branch patency rate of 96.5%\                                                                                                                                                                  \
                                        Mean aneurysm diameter\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Secondary endpoints\                                      \                                                                                                                                                                                                      No cases of spinal cord ischemia, aneurysm rupture, device migration and reported systemic complications\
                                        6.5 ± 0.9 cm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \                                                         Major adverse events at 12 months\                                                                                                                                                                     \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Major adverse events\                                     - Complications: neurological (4%), gastrointestinal (4%) and Access (4%)\                                                                                                                             Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Reintervention\                                           - Procedure/device: misplacement (9%), endoluminal obstruction (4%), thrombosis (4%) and hematoma (4%)\                                                                                                \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         - Endoleaks (22%): type I (13%) and type III (9%)\                                                                                                                                                     Non-randomised trial\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Technical endpoints\                                      \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         Reinterventions\                                                                                                                                                                                       12 months of follow up (longer time expected for sac shrinkage in large TAAA involving visceral branches)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Technical success\                                        4% of patients at 30 days (conversion to surgery)\                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Change in aneurysm sac size\                              22% of patients in 12 months (MFMS implant in 13%/stent-graft implant in 4%/conversion to surgery in 4%)\                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Volume Analysis                                           \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Technical success of 100%\                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Aneurysm diameter at 12 months\                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       - Increased in 10% of patients\                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       - remained stable in 90% of patients                                                                                                                                                                   

  Sultan S et al. [@bib6], Ireland      One hundred and three patients with mean age of 69.2 years\                                                                                                                                                                                                                                                                                                                                                                                      Retrospective multicentre cohort study (level 2b)                                   Primary endpoints at 1 year\                              Mean follow-up was 11.6 ± 3.31 months (median = 6 months)\                                                                                                                                             Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA - 72.8% of the presented pathologies:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Rupture and aneurysm-related survival\                    At 1 year:\                                                                                                                                                                                            Increasing sac volume, thrombus or diameter size was not associated with rupture\
                                        Type I - 10.7%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      All cause survival\                                       Aneurysm related survival - 91.7% (no rupture)\                                                                                                                                                        \
                                        Type II - 13.6%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Patency of visceral branches\                             All-cause survival- 86.8%\                                                                                                                                                                             MFMS implantation instigates a process of aortic remodelling involving initial thrombus deposition, which slows between 6 and 12 months\
                                        Type III - 25.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Incidence of stroke and paraplegia\                       Covered branch patency - 95.3%\                                                                                                                                                                        \
                                        Type IV - 23.3%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \                                                         Incidence of stroke - 1.9%\                                                                                                                                                                            MFMS is associated with less operative trauma, shorter procedure time and reduced hospital stay\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Technical endpoints\                                      Incidence of paraplegia - 0.99%\                                                                                                                                                                       \
                                        Arch aneurysms - 6.8%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \                                                         Total volume increased - 6.79%\                                                                                                                                                                        The study has demonstrated the proof of concept of this disruptive technology\
                                        AAA - 14.6%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Aneurysm sac volume modulation at 1 year\                 Thrombus volume increased - 21.3%\                                                                                                                                                                     \
                                        Stanford type-B dissection - 5.8%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \                                                         Maximum sac volume increased - 12.6%\                                                                                                                                                                  Limitations\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Technical success\                                        Residual flow volume decreased - 11.78%\                                                                                                                                                               \
                                        Mean aneurysm diameter 6.4 ± 1.66 cm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \                                                         Total average increase in sac volume - 5.07%\                                                                                                                                                          Brevity of follow-up study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             One-year freedom from reintervention                      \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       30-day mortality 0% and morbidity 5.8% (paraplegia 0.99%; SMA occlusion 0.99%; renal artery thrombosis 0.99%; access problem 2.9%)\                                                                    Variation in the pathologies and anatomies of patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Technical success of 97.1%\                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       One-year intervention free survival - 89.3%                                                                                                                                                            

  Sultan et al. [@bib7], Ireland        Thirty-eight patients with mean age of 71 years treated with MFMS outside the IFU\                                                                                                                                                                                                                                                                                                                                                               Retrospective multicentre cohort study\                                             Primary endpoints\                                        Mean follow-up of 10.0 ± 6.9 months:\                                                                                                                                                                  Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                                                   \                                                         Aneurysm-related deaths - 71.1%\                                                                                                                                                                       \
                                        Crawford TAAA - 39.5% of the presented pathologies:\                                                                                                                                                                                                                                                                                                                                                                                             (level 2b)                                                                          Rupture\                                                  All-cause mortality - 89.5%\                                                                                                                                                                           MFMS is a safe technique, at least in the short term (no perioperative complications), which reflects its simplicity of use\
                                        Type I - 2.6%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Aneurysm-related death\                                   \                                                                                                                                                                                                      \
                                        Type II - 18.4%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     All-cause mortality\                                      Freedom from aneurysm-related death was 37.5% at 12 months and 25% at 18 months\                                                                                                                       The MFMS is not a solution for patients living on borrowed time and should not be used indiscriminately in patients in whom other modalities of aortic repair are not feasible\
                                        Type III - 13.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Occlusion of visceral branches\                           \                                                                                                                                                                                                      \
                                        Type IV - 5.3%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Stroke\                                                   Rupture-free survival estimates were 39% at 12 months and 31.5% at 18 months\                                                                                                                          The use of MFMS must adhere to the IFU\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Paraplegia\                                               \                                                                                                                                                                                                      \
                                        66.7% of TAAA were ruptured at presentation\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \                                                         Overall survival was 29% at 12 months and 17.5% at 18 months\                                                                                                                                          This technology commands further innovative developments and robust scientific and clinical data
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Technical endpoints\                                      \                                                                                                                                                                                                      
                                        Mean aneurysm diameter\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \                                                         Visceral branch occlusions were observed in 21.0% of patients (pre-existing side branch stenosis \>50% with calcification in all of the side branches that experienced postoperative complications)\   
                                        7.1 ± 1.1 cm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Change in mean aneurysm diameter\                         No stroke and paraplegia\                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Freedom from leaks\                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Technical success\                                        The average growth rate of aneurysm diameter was 0.12 ± 0.16 cm/month\                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Freedom from reintervention                               Sac expansion occurred in all cases\                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No sac stabilization or shrinkage\                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Technical success was zero (in 81.6% of the cases there was a failure to land the device)\                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Reinterventions were required in 28.9% of patients for endoleak (failure modes I and II) or stent foreshortening\                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Factors with significance influence on the risk of aneurysm-related death: maximum aneurysm diameter (p = 0.025), previous TEVAR (p = 0.03) and inadequate overlap between MFMS devices (p \< 0.002)   

  Sultan et al. [@bib8], Ireland        Fifty-five patients with mean age of 64.5 years\                                                                                                                                                                                                                                                                                                                                                                                                 Retrospective multicentre cohort study\                                             Primary endpoint\                                         Mean follow-up was 8.2 ± 5.3 months (median 6, range 3--18)\                                                                                                                                           Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                                                   \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA - 56.4% of the presented pathologies:\                                                                                                                                                                                                                                                                                                                                                                                             (level 2b)                                                                          Aneurysm related survival and rupture at 1 year\          Aneurysm related survival at 1 year - 93.7% (no rupture occurred)\                                                                                                                                     MFMS implantation instigates a process of aortic remodelling involving initial thrombus deposition\
                                        Type I - 14.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \                                                         All cause survival at 1 year - 84.8%\                                                                                                                                                                  \
                                        Type II - 5.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Secondary endpoints\                                      Intervention free survival at 1 year - 92.4%\                                                                                                                                                          Increasing sac size did not lead to rupture\
                                        Type III - 16.4%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Type IV - 20%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       All-cause survival\                                       Covered branch patency rate of 100% at 1 year\                                                                                                                                                         The MFMS offers promise for resolution of complex thoracoabdominal pathology with off-the-shelf availability\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Visceral branch patency\                                  \                                                                                                                                                                                                      \
                                        Mean aneurysm diameter\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Adverse events\                                           Adverse Events at 1 year\                                                                                                                                                                              Further development and technical refinement is required\
                                        6.04 ± 1.66 cm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Reintervention\                                           Bleeding - 7.3%\                                                                                                                                                                                       \
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         Stroke - 3.6%\                                                                                                                                                                                         Long-term follow-up of the registry patients is mandatory before establishing a randomised controlled study\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Technical endpoints\                                      \                                                                                                                                                                                                      \
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         Reintervention at 1 year - 7.3%\                                                                                                                                                                       Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Technical success\                                        \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Rates of change in total sac, thrombus and flow volumes   Technical success of 98.2%\                                                                                                                                                                            Brevity of follow-up study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Total average increase in sac volume at 1 year - 3.26%\                                                                                                                                                Variation in the pathologies and anatomies of the patients treated\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The ratio of thrombus to total volume stayed almost constant over the 12 months at 0.48 (p = 0.743)\                                                                                                   Issues of registry: data collection, patient compliance and the variety of follow-up protocols and pharmacotherapies
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The ratio of flow to total volume fell from 0.21 to 0.12 at 12 months (p = 0.069)                                                                                                                      

  Henry et al. [@bib9], France          Eighteen high surgical risk patients (mean age 67 years)\                                                                                                                                                                                                                                                                                                                                                                                        Retrospective case series\                                                          Technical success\                                        Mean follow-up of 8 months\                                                                                                                                                                            Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                                                   \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA - 55.5%\                                                                                                                                                                                                                                                                                                                                                                                                                           (level 3)                                                                           30-day mortality\                                         Technical success of 100%\                                                                                                                                                                             MFMS can help prevent aneurysm-related mortalities while maintaining branch vessel patency\
                                        (mean age 56 year-old)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              \                                                         \                                                                                                                                                                                                      \
                                        Type I - 22.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Aneurysm-related survival\                                30-day mortality - 0% (with no complications)\                                                                                                                                                         Treatment with MFMS leads to progressive aneurysm sac thrombosis and shrinkage\
                                        Type II - 11.1%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \                                                         \                                                                                                                                                                                                      \
                                        Type IV - 22.2%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     All-cause survival\                                       At mean follow-up:\                                                                                                                                                                                    Additional study and follow up needed\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         Aneurysm- related survival of 100%\                                                                                                                                                                    \
                                        Aneurysm diameter - 60--130 mm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Side branch patency\                                      All-cause survival of 83.3%\                                                                                                                                                                           Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         Intervention-free survival of 100%\                                                                                                                                                                    \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Aneurysm diameter                                         Branch patency rate of 100%\                                                                                                                                                                           Small number of patients
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       TAAA group\                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Mean diameter reduction at 6 months (17.25 mm reduction for transverse diameter (p = 0.009) and 13.83 mm for the anteroposterior diameter (p = 0.011))                                                 

  Pane et al. [@bib10], Italy           Eight patients with mean age of 75.5 years\                                                                                                                                                                                                                                                                                                                                                                                                      Retrospective case series\                                                          Technical success\                                        Mean follow-up was 22.1 months\                                                                                                                                                                        Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                                                   \                                                         \                                                                                                                                                                                                      \
                                        Aortic Aneurysms - 50%\                                                                                                                                                                                                                                                                                                                                                                                                                          (level 3)                                                                           Mortality\                                                Technical success of 87.5%\                                                                                                                                                                            MFMS may represent a viable alternative to the endovascular approach in treating aortic conditions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        TAAA type II - 25%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Rupture\                                                  30-day mortality - 0% (with no major complications)\                                                                                                                                                   MFMS can stabilize aneurysm diameter and ensure the patency of collateral vessels\
                                        TAAA type IV - 12.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                         \                                                                                                                                                                                                      \
                                        JAAA- 12.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Secondary intervention\                                   Survival rate of 87.5% (12.5% - death unrelated to MFMS treatment)\                                                                                                                                    Limitations\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        Mean max aneurysm diameter - 6.9 cm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Major complications\                                      MFMS and branch patency rate of 100% during follow up\                                                                                                                                                 Small series - results must be confirmed by larger series and longer follow-up studies
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patency of collateral vessels\                            No secondary endovascular or open surgical procedures\                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Volume analysis                                           In aortic aneurysms, the total aneurysm volume increased 7.6% at 12 months\                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Overall trend to increase in thrombosis was observed in all cases                                                                                                                                      

  Debing et al. [@bib11], Belgium       Six patients with mean age of 74 years\                                                                                                                                                                                                                                                                                                                                                                                                          Prospective case series\                                                            Technical success\                                        Median follow-up was 10 months\                                                                                                                                                                        Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                (level 3)                                                                           \                                                         \                                                                                                                                                                                                      \
                                        67-mm type III TAAA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 30-day mortality\                                         Technical success of 100%\                                                                                                                                                                             The device preserves flow into the covered aortic branches and completed aneurysm thrombosis occurs gradually\
                                        65-mm aortic arch aneurysm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \                                                         \                                                                                                                                                                                                      \
                                        60-mm juxtarenal AAA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Aneurysm-related survival\                                30-day mortality - 16.7%\                                                                                                                                                                              The stent did not prevent rupture immediately after the implantation\
                                        59-mm juxtarenal saccular AAA\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                         \                                                                                                                                                                                                      \
                                        58-mm juxtarenal aneurysm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           All-cause survival\                                       Aneurysm-related survival - 83.3% (16.7% of patients died due to aneurysm rupture)\                                                                                                                    Limitations\
                                        72-mm juxtarenal AAA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \                                                         \                                                                                                                                                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Side branch patency\                                      Branch patency rate of 100%\                                                                                                                                                                           Small series - larger series and longer follow- up is mandatory to prove the efficacy of this technology
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Volume analysis\                                          66.7% of aneurysms were completely thrombosed between 1 and 6 months after the procedure\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Reintervention                                            At 6 months, the sac volume was decreased in 33.3% of patients, increased in 33.3% patients and remains stable in 16.7%\                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No stent migrations, retractions, thrombosis, fractures, or reinterventions                                                                                                                            

  Polydorou et al. [@bib12], Greece     Twenty-two high risk patients with mean age of 67 years\                                                                                                                                                                                                                                                                                                                                                                                         Retrospective case series\                                                          Technical success\                                        Mean follow-up for the thoracic aneurysm was 28 months, for the aortic aneurysms was 12 months and for thoracoabdominal aneurysm 12 months\                                                            Conclusions\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                \                                                                                   \                                                         \                                                                                                                                                                                                      \
                                        Crawford TAAA - 81.8% (mean aneurysm 58 mm)\                                                                                                                                                                                                                                                                                                                                                                                                     (level 3)                                                                           30-day mortality\                                         Technical success of 100%\                                                                                                                                                                             The use of the MFMS is feasible and seems to be safe for the management of aortic aneurysm with side branches\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        TAA- 4.5%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Aneurysm-related survival\                                30-day mortality - 9.1%\                                                                                                                                                                               MFMS seems to be efficacious as the side branches remain patent and the aneurysm is excluded\
                                        \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \                                                         \                                                                                                                                                                                                      \
                                        AAA- 13.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           All-cause survival\                                       Aneurysm-related survival and all-cause survival - 90.9%\                                                                                                                                              \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      Limitations\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Side branch patency\                                      The 6 and 12 month follow up CT angiograms showed patent arterial side branches, thrombus inside the sac or shrinkage of the sac\                                                                      \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                         \                                                                                                                                                                                                      Brevity of study\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Adverse Events                                            Adverse events\                                                                                                                                                                                        \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Stroke - 4.5%\                                                                                                                                                                                         Variety of pathologies
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Myocardial Infarction - 4.5%\                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       No vascular or systematic complications                                                                                                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MFMS = multilayer flow modulator stent; TAAA = thoracoabdominal aortic aneurysm; TAA = thoracic aortic aneurysm; AAA = abdominal aortic aneurysm; JAAA = juxtarenal abdominal aortic aneurysm; IFU = indications for use; TEVAR = thoracic endovascular aortic repair; COPD = chronic obstructive pulmonary disease; SMA = superior mesenteric artery.
